Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phas...(ts. Such statements includebut are not ...),Health

Date:10/28/2008

ts." Such statements include, but are not limited to, references to (i) the expected occurrence, timing and trial design of the planned development activities for ANA598, including Anadys' expectation that it will have viral load data from all three cohorts of the Phase Ib study in the first quarter of 2009; (ii) the expectation that the maximal benefit of direct antivirals will be realized when used in combination regimens incorporating multiple anti-HCV agents; (iii) the potential for once-daily or twice-daily oral dosing with ANA598; (iv) predictions of future antiviral activity of ANA598 based on plasma drug concentrations seen in the healthy volunteer study and preclinical results to date; and (v) expectations regarding the evolution of the market for HCV therapies. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving its product candidates and its ability to obtain additional funding to support its operations. Risk factors that may cause ac
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Anadys Pharmaceuticals to Present at Bio Investor Forum
2. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
5. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
6. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
7. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
8. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
9. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
10. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
11. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008